Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Nov;68(5):920–925. doi: 10.1038/bjc.1993.455

Similarity and co-expression of tumour-associated antigens recognised by different monoclonal antibodies.

H Sakahara 1, T Saga 1, K Endo 1, T Kousaka 1, M Hosono 1, H Kobayashi 1, M Shirato 1, J Konishi 1
PMCID: PMC1968720  PMID: 8217607

Abstract

The concentration of carcinoembryonic antigen (CEA), CA130, CA125, SLX, CA19-9, SPan1, and tumour-associated glycoprotein 72 (TAG-72) in the culture supernatant of 15 cancer cell lines and in the sera of 58 cancer patients was measured, and the co-expression of these antigens was examined by double determinant immunoradiometric assays. The high correlation coefficient of the concentrations and significant binding in the double determinant assays indicated a close relationship between CA125 and CA130 and between CA19-9 and SPan1. There was variable binding of the 125I-labelled anti-SLX, anti-CA19-9, and anti-SPan1 antibodies to anti-CA130 beads that had been pre-incubated with the culture supernatants, suggesting the presence of the epitopes of SLX, CA19-9, and SPan1 on the molecule expressing CA130. Similarly, the epitopes of SLX, CA19-9, and SPan1 could be present on the molecule expressing CEA. 125I-labelled anti-CA19-9, anti-SLX, and anti-TAG-72 antibodies were bound in variable proportions to anti-CA130 beads or to anti-CEA beads that had been pre-incubated with patients' sera. However, CEA and CA130 were not expressed on the same molecule, either in the culture supernatant, or in patients' sera. In conclusion, the carbohydrate epitopes of CA19-9, SPan1, SLX, and TAG-72 could be present on the molecule recognised by the anti-CA130 or anti-CEA antibody; however, the epitopes of CA130 and CEA did not co-exist on the same molecule.

Full text

PDF
920

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  2. Chung Y. S., Ho J. J., Kim Y. S., Tanaka H., Nakata B., Hiura A., Motoyoshi H., Satake K., Umeyama K. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer. 1987 Oct 1;60(7):1636–1643. doi: 10.1002/1097-0142(19871001)60:7<1636::aid-cncr2820600736>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  3. Davis H. M., Zurawski V. R., Jr, Bast R. C., Jr, Klug T. L. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res. 1986 Dec;46(12 Pt 1):6143–6148. [PubMed] [Google Scholar]
  4. Del Villano B. C., Brennan S., Brock P., Bucher C., Liu V., McClure M., Rake B., Space S., Westrick B., Schoemaker H. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983 Mar;29(3):549–552. [PubMed] [Google Scholar]
  5. Fukushi Y., Nudelman E., Levery S. B., Hakomori S., Rauvala H. Novel fucolipids accumulating in human adenocarcinoma. III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3NeuAcV3III3Fuc2nLc6). J Biol Chem. 1984 Aug 25;259(16):10511–10517. [PubMed] [Google Scholar]
  6. Hanisch F. G., Uhlenbruck G., Dienst C., Stottrop M., Hippauf E. Ca 125 and Ca 19-9: two cancer-associated sialylsaccharide antigens on a mucus glycoprotein from human milk. Eur J Biochem. 1985 Jun 3;149(2):323–330. doi: 10.1111/j.1432-1033.1985.tb08929.x. [DOI] [PubMed] [Google Scholar]
  7. Ho J. J., Chung Y. S., Fujimoto Y., Bi N., Ryan W., Yuan S. Z., Byrd J. C., Kim Y. S. Mucin-like antigens in a human pancreatic cancer cell line identified by murine monoclonal antibodies SPan-1 and YPan-1. Cancer Res. 1988 Jul 15;48(14):3924–3931. [PubMed] [Google Scholar]
  8. Hosono M. N., Endo K., Sakahara H., Watanabe Y., Saga T., Nakai T., Hosono M., Nakajima T., Onoyama Y., Konishi J. Different antigenic nature in apparently healthy women with high serum CA 125 levels compared with typical patients with ovarian cancer. Cancer. 1992 Dec 15;70(12):2851–2856. doi: 10.1002/1097-0142(19921215)70:12<2851::aid-cncr2820701222>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  9. Ishiwata I., Ishiwata C., Soma M., Nozawa S., Ishikawa H. Characterization of newly established human ovarian carcinoma cell line--special reference of the effects of cis-platinum on cellular proliferation and release of CA125. Gynecol Oncol. 1987 Mar;26(3):340–354. doi: 10.1016/0090-8258(87)90026-6. [DOI] [PubMed] [Google Scholar]
  10. Johnson V. G., Schlom J., Paterson A. J., Bennett J., Magnani J. L., Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986 Feb;46(2):850–857. [PubMed] [Google Scholar]
  11. Kannagi R., Fukushi Y., Tachikawa T., Noda A., Shin S., Shigeta K., Hiraiwa N., Fukuda Y., Inamoto T., Hakomori S. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. Cancer Res. 1986 May;46(5):2619–2626. [PubMed] [Google Scholar]
  12. Kjeldsen T., Clausen H., Hirohashi S., Ogawa T., Iijima H., Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res. 1988 Apr 15;48(8):2214–2220. [PubMed] [Google Scholar]
  13. Klug T. L., Bast R. C., Jr, Niloff J. M., Knapp R. C., Zurawski V. R., Jr Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984 Mar;44(3):1048–1053. [PubMed] [Google Scholar]
  14. Kunimatsu M., Endo K., Nakashima T., Awaji T., Saga T., Watanabe Y., Kawamura Y., Ohta H., Koizumi M., Sakahara H. Development of new immunoradiometric assay for CA 125 antigen using two monoclonal antibodies produced by immunizing lung cancer cells. Ann Nucl Med. 1988 Nov;2(2):73–79. doi: 10.1007/BF03164948. [DOI] [PubMed] [Google Scholar]
  15. Lan M. S., Bast R. C., Jr, Colnaghi M. I., Knapp R. C., Colcher D., Schlom J., Metzgar R. S. Co-expression of human cancer-associated epitopes on mucin molecules. Int J Cancer. 1987 Jan 15;39(1):68–72. doi: 10.1002/ijc.2910390112. [DOI] [PubMed] [Google Scholar]
  16. Magnani J. L., Nilsson B., Brockhaus M., Zopf D., Steplewski Z., Koprowski H., Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982 Dec 10;257(23):14365–14369. [PubMed] [Google Scholar]
  17. Magnani J. L., Steplewski Z., Koprowski H., Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983 Nov;43(11):5489–5492. [PubMed] [Google Scholar]
  18. Masuho Y., Zalutsky M., Knapp R. C., Bast R. C., Jr Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res. 1984 Jul;44(7):2813–2819. [PubMed] [Google Scholar]
  19. Matsuoka Y., Nakashima T., Endo K., Yoshida T., Kunimatsu M., Sakahara H., Koizumi M., Nakagawa T., Yamaguchi N., Torizuka K. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells. Cancer Res. 1987 Dec 1;47(23):6335–6340. [PubMed] [Google Scholar]
  20. Muraro R., Kuroki M., Wunderlich D., Poole D. J., Colcher D., Thor A., Greiner J. W., Simpson J. F., Molinolo A., Noguchi P. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res. 1988 Aug 15;48(16):4588–4596. [PubMed] [Google Scholar]
  21. Saga T., Endo K., Nakashima T., Awaji T., Koizumi M., Kawamura Y., Watanabe Y., Konishi J., Nonogaki H., Nanbu Y. Construction of an immunoradiometric assay for ovarian cancer associated antigen CA125 recognizing different antigenic determinant. Acta Obstet Gynecol Scand. 1990;69(2):175–181. doi: 10.3109/00016349009006164. [DOI] [PubMed] [Google Scholar]
  22. Sakahara H., Endo K., Nakajima K., Nakashima T., Koizumi M., Ohta H., Hidaka A., Kohno S., Nakano Y., Naito A. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer. 1986 Apr 1;57(7):1324–1326. doi: 10.1002/1097-0142(19860401)57:7<1324::aid-cncr2820570712>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  23. Sears H. F., Herlyn M., Del Villano B., Steplewski Z., Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol. 1982 Apr;2(2):141–149. doi: 10.1007/BF00916898. [DOI] [PubMed] [Google Scholar]
  24. Yu Y. H., Schlossman D. M., Harrison C. L., Rhinehardt-Clark A., Soper J. T., Klug T. L., Zurawski V. R., Jr, Bast R. C., Jr Coexpression of different antigenic markers on moieties that bear CA 125 determinants. Cancer Res. 1991 Jan 15;51(2):468–475. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES